Ageing Science


Tuesday 4th May
Wednesday 5th May
Thursday 6th May
Friday 7th May

Tuesday 4th May


13:00 CET 12:00 BST 07:00 ET

Video partnering meetings

Video partnering meetings run over a 24hr period, starting from 12am each day and running until 12midnight in your local time, to allow for cross-timezone video meetings.


15-16 CET 14-15 BST 09-10 ET

Special session: 7 Sign of Longevity Revolution

We have entered a new and exciting time. Tech breakthroughs are changing the face of medicine and making it possible for us to cure previously fatal diseases. The longevity revolution means we will all be living longer and healthier than ever before!

  • How the environment is shifting to promote longevity
  • How healthcare and its main players are transforming
  • Technologies that’ll enable us to live longer than ever

Sergey Young, Founder, Longevity Vision Fund

Sergey Young, Founder, Longevity Vision Fund

 

Wednesday 5th May


12-13 CET 11-12 BST 06-07 ET

Changing the narrative on ageing science to secure funding for fundamental research

COVID-19 has changed the narrative on the biology of ageing and its impact on health. This session explores how to better communicate the concept of ageing science to funding bodies in the wake of COVID-19, encouraging open dialogue between researchers and funding bodies.

Joao Pedro De Magalhaes, Profession, Institute of Ageing and Chronic Disease, University of Liverpool
Claire Stewart, Professor of Stem Cell Biology, Stem Cells, Ageing and Molecular Physiology Unit, Liverpool John Moores University
Moderator: Lynne Cox, PI Lab of Ageing and Cell Senescence, University of Oxford

Joao Pedro De Magalhaes, Profession, Institute of Ageing and Chronic Disease, University of Liverpool    Claire Stewart, Professor of Stem Cell Biology, Stem Cells, Ageing and Molecular Physiology Unit, Liverpool John Moores University    Lynne Cox, Associate Professor, University of Oxford


13-14 CET 12-13 BST 07-08 ET

Video breakout: Biology of ageing (Europe & Middle East)

A valuable way to meet an intimate, yet interactive group of European and Middle Eastern attendees in an informal setting, paving the way for thought provoking discussions and valued connections on the subject of biology of ageing. This is a breakout roundtable video meeting for up to 20 attendees, where everyone has the opportunity to contribute to an open-ended discussion. As such it is unmoderated and unstructured, allowing participants to set themes, ask questions and offer advice. Please have your Cameras and Mics on to get the most from this session.


15-16 CET 14-15 BST 09-10 ET

What has COVID taught us about the biology of ageing?

Why are older people disproportionally affected by COVID? Why does COVID appear to accelerate the ageing process? How does the biology of long COVID differ and how does that advance our understanding of the biology of ageing? This session looks at everything we’ve learned in the past twelve months about COVID and the biology of ageing.

Janet Lord, Director of the Institute of Inflammation and Ageing, University of Birmingham
James Kirkland, Director of the Robert and Arlene Kogod Centre on Aging, Mayo Clinic; President Elect, American Federation for Aging
Moderator: Nir Barzilai, Director, Institute for Aging Research, Albert Einstein College of Medicine

Janet Lord, Director of the Institute of Inflammation and Ageing, University of Birmingham    James Kirkland, Director of the Robert and Arlene Kogod Centre on Aging, Mayo Clinic; President Elect, American Federation for Aging    Nir Barzilai, Director, Institute for Aging Research, Albert Einstein College of Medicine


16-17 CET 15-16 BST 10-11 ET

Advances in novel discovery tools and delivery systems for ageing science applications

Ageing science demands a new set of drug discovery and delivery tools. This session explores novel drug discovery and delivery systems and how they are being applied to improve ageing science research.

Michael Zemel, Founder and Chief Scientific Officer, Nusirt
Christopher Trummer
, CEO, Celeris Therapeutics
Carolina Reis Oliveira
, CEO, OneSkin
Hank Garcia
, Head of Ageing R&D, Oisin Therapeutics
Moderator: Siham Ceballos, Founder and Managing Partner, Bioartemis

Michael Zemel, Founder and Chief Scientific Officer, Nusirt    Christopher Trummer, CEO, Celeris Therapeutics    Carolina Reis Oliveira, Co-Founder & CEO, OneSkin 300x    Hank Garcia, Head of Ageing R&D, Oisin Therapeutics    Siham Ceballos, Founder and Managing Partner, Bioartemis


17-18 CET 16-17 BST 11-12 ET

What have we learned from setbacks and how to move the field forward post-COVID

2020 was a year of massive disruption for ageing science. On one hand, COVID-19 offered a new paradigm in which to study and explain the benefits of ageing science to investors, healthcare providers and regulators. On the other, two high profile trials didn’t deliver the results that were needed to propel the field into the mainstream. This session looks at what was learned and how to move forward.

Michael Hufford, Co-Founder and CEO, Lygenesis
Maddalena Adorno
, Co-Founder and CEO, Dorian Therapeutics
Moderator: Natalia Novac
, Senior Director Emerging Technology & Innovation, Lilly New Ventures, Eli Lilly

Michael Hufford, Co-Founder and CEO, Lygenesis    Maddalena Adorno, Co-Founder and CEO, Dorian Therapeutics    Natalia Novac, Senior Director, Emerging Technologies and Innovation, Corporate Business Development, Eli Lilly


18-19 CET 17-18 BST 12-13 ET

Investing in longevity biotech – market opportunities, gaps and priorities

The worlds’ most prominent investors in longevity biotech share their thoughts on the biggest areas of opportunity, gaps in the market and framing priorities to bring more investment into the field.

Aubrey De Grey, Co-Founder and Chief Science Officer, SENS Foundation
Ronjon Nag, Managing Director and Founder, R42 Group
Diana Saraceni
, Partner, Panakes Partners
Alexandra Bause
, Investment Director, Apollo Ventures
Moderator: Patrick Burgermeister, Partner, KIZOO Technology Ventures

Aubrey De Grey, Co-Founder and Chief Science Officer, SENS Foundation     Ronjon Nag, Managing Director and Founder, R42 Group    Diana Saraceni, Partner, Panakes Partners    Alexandra Bause, Investment Director, Apollo Ventures    Patrick Burgermeister, Partner, KIZOO Technology Ventures


19-20 CET 18-19 BST 13-14 ET

Video breakout: Biology of ageing (North America)

A valuable way to meet an intimate, yet interactive group of North American attendees in an informal setting, paving the way for thought provoking discussions and valued connections on the subject of biology of ageing. This is a breakout roundtable video meeting for up to 20 attendees, where everyone has the opportunity to contribute to an open-ended discussion. As such it is unmoderated and unstructured, allowing participants to set themes, ask questions and offer advice. Please have your Cameras and Mics on to get the most from this session.

 

Thursday 6th May


12-13 CET 11-12 BST 06-07 ET

Roundtable: How can UK SPINE+ boost the UK geroscience industry?

A look at UKSPINE’s work to boost the UK geroscience industry, including key current and future projects and routes for partners to take part.

Chas Bountra, Pro-Vice Chancellor for Innovation and Professor of Translational Medicine, University of Oxford
Mike Ferguson, Regius Professor of Life Sciences, University of Dundee
Elizabeth Sapey
, Professor of Acute and Respiratory Medicine, Institute of Inflammation and Ageing, University of Birmingham
Moderator: Chris Molloy, Chief Executive Officer, Medicines Discovery Catapult

Chas Bountra, Pro-Vice Chancellor for Innovation and Professor of Translational Medicine, University of Oxford    Mike Ferguson, Regius Professor of Life Sciences, University of Dundee    Elizabeth Sapey, Professor of Acute and Respiratory Medicine, Institute of Inflammation and Ageing, University of Birmingham    Moderator: Chris Molloy, Chief Executive Officer, Medicines Discovery Catapult


13-14 CET 12-13 BST 07-08 EST

Introducing Longevity as a Service (LaaS)™: bringing longevity innovation to life and businesses

Join NICA for the launch of the Longevity as a Service ™ cluster, bringing together a range of companies, collaborating to build holistic longevity offerings - turning proclamations into actions, intentions into practical, digitally enabled, data driven and market wise solutions, now.

The NICA mission – to democratize longevity - bring science directly into people’s daily lives, with cross generations - citizens or employees - not only beneficiaries of longer, healthier lives, but initiators. Grounded in core ethical principles, we involve scale-ups and start ups, are an advisory interface for investors and provider of solutions for HR managers and CMOS, as a gateway of people’s wealth, health, happiness.

Nic Palmarini, Director, National Innovation Centre for Ageing
Lynne Corner, Co-Founder and Director, VOICE; COO, National Innovation Centre for Ageing
Patrick Bonnett
, Director of Development, National Innovation Centre for Ageing
Shiti Rastogi-Manghani, Co-Founder and CEO, BreatheHappy
Mark Birch-Machin, Founder, Skin Life Analytics
Gordan Lauc, Founder and CEO, GlycanAge
Guido Cornettone
, CEO, SoLongevity
Daryl Arnold
, Founder and CEO, ConnectedLife

Nic Palmarini, Director, National Innovation Centre on Ageing    Lynne Corner, Co-Founder and Director, VOICE; COO, National Innovation Centre on Ageing    Patrick Bonnett, Development Director, National Innovation Centre on Ageing    Shiti Rastogi-Manghani, Co-Founder and CEO, BreatheHappy    Mark Birch-Machin, Founder, Skin Life Analytics    Gordon Lauc, Founder and CEO, GlycanAge    Guido Cornettone, CEO, SoLongevity    Daryl Arnold, Founder and CEO, ConnectedLife


14-15 CET 13-14 BST 08-09 ET

Real-world applications of ageing biology in aesthetics, nutrition and consumer health

Ageing science is becoming increasingly prevalent in life sciences, aesthetics, nutrition and consumer health. This session explores how assorted disciplines are incorporating the biology of ageing into research and development of new products to enhance human healthspan.

Stephanie Manson-Brown, Head of Clinical Development, VP Allergan Aesthetics R&D, AbbVie
Sibylle Jager, Scientific Directorate Manager, L’Oreal
Joanna Bensz
, Founder and CEO, Longevity Center
Ian Rollo
, Principal Scientist, Gatorade Sports Science Institute, PepsiCo
Moderator: Sandrine Rey-Salco, Medical Doctor, Gerontologist and Functional Assessor, Centre for Health and Disability Assessments

Stephanie Mason-Brown, Head of Clinical Development, VP Allergan Aesthetics R&D, AbbVie    Sibylle Jager, Scientific Directorate Manager, L’Oreal    Joanna Bensz, Founder and CEO, Longevity Centre    Ian Rollo, Principal Scientist, Gatorade Sports Science Institute, PepsiCo    Sandrine Rey-Salco, Medical Doctor, Gerontologist and Functional Assessor, Centre for Health and Disability Assessments-1


15-16 CET 14-15 BST 09-10 ET

Novel therapeutic approaches

The field is bursting with novel approaches to harness the biology of ageing to extend healthspan. This session looks at novel therapeutic approaches including targeting mRNA, mitochondria, senomorphics and epigenetic modifications.

Reenie McCarthy, Chief Executive Officer, Stealth Bio
Lorna Harries, Chief Scientific Officer, Senisca
Jay Sarkar
, Co-Founder, Turn Biotechnologies
Moderator:
David Brown, Senior Director, Scientific and Technical Innovation, Stealth Biotherapeutics

Reenie McCarthy, Chief Executive Officer, Stealth Bio    Lorna Harries, Chief Scientific Officer, Senisca    Jay Sarkar, Co-Founder, Turn Biotechnologies    David Brown, Senior Director, Scientific and Technical Innovation, Stealth Biotherapeutics


16-17 CET 15-16 BST 10-11 ET

Roadmap to commercialisation – examining clinical and regulatory pathways for longevity therapeutics

This session examines how to overcome clinical and regulatory challenges for a new therapeutic class.

Thomas Hughes, Chief Executive Officer, Navitor
Joan Mannick
, Head of Research & Development, Life Biosciences
David Roblin
, Chief Operating Officer, Juvenescence
Moderator: Steven Braithwaite, Chief Scientific Officer, Alkahest

Thomas Hughes, Chief Executive Officer, Navitor    Joan Mannick, Head of Research & Development, Life Biosciences    David Roblin, Chief Operating Officer, Juvenescence    Steven Braithwaite, Chief Scientific Officer, Alkahest


17-18 CET 16-17 BST 11-12 ET

Creating consensus on the Biology of Ageing Paradigm

In 2020 a survey of leading academics in the field of ageing science acknowledged a lack of consensus on a biology of ageing paradigm, and the need for an agreed interdisciplinary framework. This roundtable attempts to establish agreement on a common paradigm in ageing biology including vocabulary, credibility framework and guiding principles.

Thomas Rando, Co-Founder, Fountain Therapeutics
Eric Verdin
, Chief Executive Officer, Buck Institute
Moderator: Samuel Agus, Chief Medical Officer, Biophytis

Thomas Rando, Co-Founder and Chair of Board of Directors, Fountain Therapeutics    Eric Verdin, Chief Executive Officer, Buck Institute    Samuel Argus, Chief Medical Officer, Biophytis

 

Friday 7th May


13:00 CET 12:00 BST 07:00 ET

Video partnering meetings

Video partnering meetings run over a 24hr period, starting from 12am each day and running until 12midnight in your local time, to allow for cross-timezone video meetings.

DOWNLOAD BROCHURE